INTRODUCTION
Allo-SCT has proven to be an effective therapy for a variety of life-threatening malignancies. However, allo-SCT is limited by the immunologic recognition and destruction of host tissues, termed GVHD, which continues to be the major source of morbidity and mortality following allo-SCT. GVHD affects 50-70% of patients receiving allo-SCT. 1 Of note, severe acute gastrointestinal GVHD (GI-GVHD) occurring early after allo-SCT is likely the most serious complication and is a major determinant of long-term survival. 2, 3 The gold standard method for the diagnosis of GI-GVHD remains based on clinical symptoms. 4 The current procedure to confirm GI-GVHD is based on endoscopic examination and histology, mainly to exclude differential diagnosis. However, this approach remains unsatisfactory in most cases (lack of specificity and sensitivity for histology). Also, only the evolution of acute GI-GVHD during the initial weeks will ultimately define the severity of GVHD. 5 At present, noninvasive tests for assessment of GI-GVHD activity are desirable. According to a recently published study, the inflammatory activity associated with acute GI-GVHD can be assessed by 18 F-FDG PET/CT. 6 The latter study indicated that FDG-PET might be a sensitive and specific noninvasive technique to assess GI-GVHD, but data in this field is still sparse. With this background, the current pilot prospective study aimed to evaluate the predictive value of 18 F-FDG PET/CT for early diagnosis of acute GI-GVHD.
PATIENTS AND METHODS

Study design and patients selection
This prospective evaluation was conducted at the University Hospital of Nantes (Nantes, France). Written informed consent was obtained from each patient and donor in accordance with the principles of the declaration of Helsinki. From January 2009 to March 2010, 42 adult patients who received an allo-SCT and accepted to participate to the study were included in this analysis. Written informed consent was obtained from each patient. The study was approved by the local institutional review boards. Patient and graft characteristics are shown in Table 1 . For inclusion in this study, there were no restrictions in terms of diagnoses, stem cell sources or conditioning regimens. All patients received the preparative regimen as inpatients in private rooms, and remained hospitalized until hematopoietic and clinical recovery. Twenty donors (48%) were HLAidentical sibling donors, 15 (36%) were HLA-matched unrelated donors and 7 (17%) were mismatched unrelated donors. The stem cell source was BM in four cases (10%), G-CSF-mobilized PBSCs in 33 cases (78%) and double umbilical cord blood cells in the remaining 5 cases (12%). In this series, the median age was 55 (range, 21-69) years. Three patients (7%) received a standard myeloablative conditioning regimen, while 39 patients received a reduced-intensity conditioning (93%). Supportive care and antimicrobial prophylaxis were reported previously. 7 For GVHD prophylaxis, patients who underwent a myeloablative conditioning received CsA and short-course MTX. Patients from the reduced-intensity conditioning group received CsA alone in case of a matched related donor, or CsA and mycophenolate mofetil (MMF) in case of an alternative donor. CsA was administered at a dose of 3 mg/kg/day by continuous i.v. infusion starting from day 3 or 2, and changed to twice daily oral dosing as soon as tolerated. 8 MMF was given at a fixed oral dose of 2 g/day. No treatment adjustment was performed for MMF. MMF was tapered over 4 weeks starting from day 60 and CsA from day þ 90 if no GVHD appeared. Of note, during the whole study period supportive care was the same. CMV infection management was also homogeneous. All blood products were filtered, irradiated and CMV screened. In the first 100 days after allo-SCT, patients were assessed at least once per week for CMV reactivation by PCR assay to initiate preemptive ganciclovir therapy.
Diagnosis of acute GI-GVHD
For the purpose of this analysis, the reference diagnosis of acute GI-GVHD was based on the modified Glucksberg grading system proposed in 1995, 4 that was used to establish a severity score for each organ (skin, gastrointestinal tract and liver) from 0 to 4 according to clinical symptoms. These stages were combined to obtain an overall severity score from 0 to IV. The modified Glucksberg grading system was used to include upper gastrointestinal acute GVHD. Bacteriological, virological and parasitological stool culture, a search for Clostridium difficile toxin in stool and virus DNA screening in plasma (CMV, adenovirus (ADV)y) were systematically performed to exclude other differential diagnoses. Upper gastrointestinal endoscopy and a rectosigmoidoscopy with staged biopsy sampling of the mucosa was performed when it was necessary, to confirm the diagnosis of GI-GVHD and mainly exclude other potential diagnoses, according to the patient's symptoms and laboratory findings. Whenever biopsies were performed, histopathological data were used to assess the diagnosis of GI-GVHD according to the histopathologic score of acute GI-GVHD developed by Sale et al. 18 F-FDG PET/CT were performed on a Discovery LS PET scanner hybrid (GE Medical Systems, Waukesha, WI, USA) 60-80 min after i.v. injection of 5-7 MBq/kg of 18 F-FDG. Acquisitions ranged from the supra-orbital region to mid-thigh. Images were reconstructed according to the OSEM iterative reconstruction algorithm with and without attenuation correction. All recorded images were interpreted independently by two nuclear medicine specialists (CB-M and ML) who were blinded to patients' clinical data and symptoms. Also, per study protocol, this was a non-interventional study. Therefore, results of the 18 F-FDG PET/CT were not made available to the attending physician and were not used to modify the standard management and treatment of patients. The 18 F-FDG PET/CT examination was performed in patients who fasted for at least 6 h to prevent hyperinsulinism and limit myocardial fixation. Capillary blood glucose was measured before injection of the radiotracer. To avoid fixing striated muscle, patients had to observe strict rest for 1 h after administration of tracer. Finally, patients had to urinate before image acquisition to limit hypermetabolism of the urinary tract and bladder that may hinder the interpretation of the examination. At visual analysis, any focal or diffuse increase of FDG uptake exceeding the digestive activity and physiological liver background was defined as pathological. Liver background was used as threshold in reference to previous studies reporting the value interest of 18 F-FDG PET/CT in the diagnosis of chronic inflammatory bowel diseases 10, 11 The different regions of the gastrointestinal tract analyzed were: esophagus, stomach, intestine (duodenum and ileum), colon (cecum, ascending colon, descending colon and sigmoid).
A semiquantitative analysis was performed for pathological examination; regions of interest were drawn on the region of maximum uptake of FDG determined by visual analysis, allowing to define the maximum SUV (SUVmax).
Statistical methods
To assess the predictive value of 18 F-FDG PET/CT, only gastrointestinal symptoms occurring up to 4 weeks after completion of 18 F-FDG PET/CT were considered. A true positive (TP) 18 F-FDG PET/CT test corresponded to an increase of focal or diffuse FDG uptake, exceeding physiological digestive activity and whose character was related to pathological diagnosis of acute GI-GVHD occurring up to 4 weeks after completion of the review. A true negative (TN) 18 F-FDG PET/CT test was defined by the absence of abnormalities found in the gastrointestinal tract, confirmed by the absence of occurrence of acute GI-GVHD symptoms within 4 weeks after the examination. A false negative (FN) corresponded to the absence of abnormalities found in the gastrointestinal tract in PET/CT in patients who developed acute GI-GVHD and required systemic therapy during the 4 weeks following examination. A false positive (FP) corresponded to an increase of focal or diffuse FDG uptake, exceeding physiological activity of digestive tract in patients who remained free of acute GI-GVHD symptoms within 4 weeks after the examination. 18 F-FDG PET/CT results and the reference diagnosis methods of acute GI-GVHD were compared using sensitivity (Se), specificity (Sp), positive predictive value (PPV), negative predictive value (NPV) and accuracy. Finally, the SUVmax values between grades of severity of acute GI-GVHD and location of pathologic foci on gastrointestinal tract were compared using the nonparametric MannWhitney test. For all statistical tests, a P-value o0.05 was considered significant. Statistical analyses were made using Stata (StataCorp LP, Lakeway Drive, TX, USA). 
RESULTS
Diagnosis of acute GI-GVHD and outcome
In this cohort, 10 out of 42 patients (24%) developed signs and symptoms of acute GI-GVHD according to standard criteria, during the follow-up period of interest (until 4 weeks after performance of 18 F-FDG PET/CT). Data are summarized in Table 2 . GI-GVHD signs developed after a median time of 27 (range 10-55) days after allo-SCT. The remaining 32 patients (76%) did not develop any clinical sign of GI-GVHD during the follow-up period of interest. None of the patients in both groups presented C. difficile or CMV colitis during the follow-up period of interest. Among the 10 patients who developed GI-GVHD symptoms, 3 patients had a grade 1, 4 had a grade 2, 1 had a grade 3 and 2 had a grade 4 according to the modified Glucksberg grading system. 12 The two patients with a grade 4 acute GI-GVHD died because of refractory GI-GVHD despite the use of high-dose corticosteroids and secondline immunosuppressive therapy. The remaining eight patients with acute GI-GVHD symptoms had a favorable evolution: three patients with grade 1 GI-GVHD signs improved spontaneously after transient oral intake discontinuation without introduction of systemic steroids; the remaining five patients with grade 2 and grade 3 GI-GVHD responded to systemic steroids (2 mg/kg/day). Histopathology data was available for 9 cases from the 10 patients who developed signs of GI-GVHD. Histopathology was not performed in the one patient with grade 1 acute GI-GVHD. 18 
F-FDG PET/CT results
In this cohort, 18 F-FDG PET/CT was performed at a median of 28 (range, 24-38) days after allo-SCT. 18 F-FDG PET/CT data review was positive in 15 cases (36%) (9 TP cases and 6 FP cases) and negative in 27 cases (64%; 26 TN cases and 1 FN case) at visual analysis. Se, Sp, PPV, NPV and accuracy of 18 F-FDG PET/CT for the diagnosis of acute GI-GVHD were, respectively 90%, 81%, 60%, 96% and 83% (Table 3) . Table 2 summarizes the results of 18 F-FDG PET/CT according to acute GI-GVHD clinical and histological grades.
True positive patients (TP) Figure 1 shows the results of a TP patient. For the nine patients with both GI-GVHD symptoms and positive 18 F-FDG PET/CT, acute GI-GVHD was classified as grade 1 (2 patients), grade 2 (4 patients), grade 3 (1 patient) or grade 4 (2 patients). At time of 18 F-FDG PET/ CT, four of these nine patients (44%) proved to have some clinical signs of acute GI-GVHD, with a median onset of symptoms of 19 (range, 10-23) days after allo-SCT and a median time of 18 F-FDG PET/CT of 28.5 (range, 24-35) days after allo-SCT. Retrospectively, it proved that two of these four patients were actually already receiving corticosteroid therapy (1 and 2 mg/kg/day) according to the attending physician decision, 6 and 25 days before the 18 F-FDG PET/CT, respectively. The remaining five patients (66%) were free of GI-GVHD symptoms at time of completion of 18 F-FDG PET/CT, but ultimately developed signs of acute GI-GVHD at a median of 12 (range, 2-28) days after 18 F-FDG PET/CT completion. In TP patients, increased FDG uptake involved the stomach (15%), duodenum (8%), ileum (31%), cecum (8%), ascending colon (23%), descending colon (8%) and sigmoid (8%) 3.8-6 ). There were no significant differences in SUVmax values between GVHD colonic localizations and GVHD gastrointestinal localizations (P ¼ 0.19). Also, there were no significant differences of SUVmax values between grade 1-2 GI-GVHD (median SUVmax ¼ 5.5) and grade 3-4 GI-GVHD (median SUVmax ¼ 5.6; P ¼ 1.0). Finally, among the two patients with grade 1 GI-GVHD and a positive 18 F-FDG PET/CT, one patient presented only upper GI-GVHD with a 18 F-FDG PET/CT positive on the stomach, the duodenum and the ileum, the second patient presented upper and lower GI-GVHD. Figure 2 shows an example of the results of a TN patient. In the 26 (62%) patients without symptoms of acute GI-GVHD and having a negative 18 F-FDG PET/CT, the examination was performed at a median of 29 (range, 24-38) days after allo-SCT. During the 4 weeks of the following period of interest after completion of 18 F-FDG PET/CT, none of these 26 patients showed any clinical symptoms that could suggest a diagnosis of acute GI-GVHD, furthermore, if we extend the follow-up period, none of the patients presented GI-GVHD in the first 100 days after allo-SCT. The NPV of 18 F-FDG PET/CT was calculated at 96%.
True negative patients (TN)
False positive patients (FP)
Six patients (14.5%) presented a positive 18 F-FDG PET/CT while they were, and remained free from signs of acute GI-GVHD. For two of these patients, it appeared later that false positivity was related to daily treatment with metformin (not revealed to the nuclear medicine specialists who interpreted the tests) as previously described. 13 Figure 3 shows the results of one of the two FP patients who were taking metformin. For another one FP patient, false positivity was likely related to the presence of severe peptic esophagitis, proven later by endoscopy. For the three other FP patients, GI-GVHD diagnosis was not made, and no other explanation could be found (including infectious causes such as Clostridium difficile or CMV colitis, which were excluded).
False negative patients (FN)
Only one patient with a negative 18 F-FDG PET/CT performed at day 27 after allo-SCT developed symptoms of acute grade 1 PET/CT and GVHD C Bodet-Milin et al GI-GVHD. Indeed, these symptoms started 20 days after allo-SCT and included nausea and diarrhea. The sigmoidoscopy examination performed at day 22 after allo-SCT (5 days before the 18 F-FDG PET/CT examination) was visually normal. However, the diagnosis of GI-GVHD was ultimately confirmed by histopathologic analysis, which found evidence for apoptotic colitis. 
DISCUSSION
Results from the current prospective analysis showed that the inflammatory activity of the gastrointestinal tract associated with acute GI-GVHD could be assessed by 18 F-FDG PET/CT. In our cohort, 9 of 10 patients with proven acute GI-GVHD had a positive 18 F-FDG PET/CT, reflecting a 90% Se for detection of acute GI-GVHD, similar to the Se calculated in the study by Stelljes et al. (82%). On the other hand, only one patient presented with a FN 18 F-FDG PET/CT result. This patient presented subsequently grade 1 acute GI-GVHD, which resolved quickly after symptomatic measures and without any additional systemic immunosuppressive therapy. Interestingly, endoscopy performed 5 days before 18 F-FDG PET/CT was also negative in this patient. 18 F-FDG PET/CT was positive in nine patients, including five patients before developing clinical symptoms of GI-GVHD, suggesting that this imaging technique would allow for early diagnosis of acute GVHD in some cases. Interestingly, in two other symptomatic patients, 18 F-FDG PET/CT was positive despite the introduction of systemic steroid therapy up to 3 weeks before the examination. While the Se of 18 F-FDG PET/CT in our study was similar to that found by Stelljes et al., 6 Sp was lower (81% versus 100%). This apparent discrepancy can be explained by the fact that our study included all consecutive patients who were transplanted during the study period, irrespective of GI-GVHD symptoms, while Stelljes study included only patients with already suspected symptoms of acute GI-GVHD. In addition, in our study physicians who analyzed 18 F-FDG PET/CT data were blinded to patients' symptoms and to the conclusions of the attending transplant physician. Moreover, we have applied very stringent inclusion criteria in terms of 18 F-FDG PET/CT interpretation and nuclear medicine physicians were blinded to patients' clinical data. The latter may have lead to false positive results in two patients in whom it was shown retrospectively that they were receiving metformin, a drug known to induce a significant increase of FDG uptake along the wall and into the intestinal lumen. 13 These two false positive results would have probably been avoided today thanks to the systematic discontinuation of metformin 2-3 days before the completion of 18 F-FDG PET/CT. Indeed, two recent studies have shown that stopping metformin 2-3 days before the completion of 18 F-FDG PET/CT could decrease significantly the gastrointestinal uptake of FDG.
14,15 Considering these two patients as false positives leads to a decreased SP and PPV in our study. Moreover, it is well known that 18 F-FDG is not a specific tracer to distinguish active inflammatory tissues from infectious diseases. New PET tracers targeting specific targets are under clinical investigation in other settings and might be used more specifically than 18 F-FDG in GI-GVHD. Washington et al. 16 demonstrated that the crypt cell apoptosis was one of the histological hallmark of GI-GVHD. Thus, apoptotic cells might be considered as a good target to improve Sp of PET imaging in GI-GVHD. 18F-labeled 2-(5-fluoropentyl)-2-methyl malonic acid ( 18 F-ML-10) is a small molecule probe for PET and derived from a family of biomarkers for apoptosis. 17 Preclinical studies have shown that 18 F-ML-10 manifested selective binding to apoptotic cell with favorable biodistribution profile. Hoglund et al. 18 have recently published the first human study using 18 F-ML-10, in volunteer patients with favorable and promising results in dosimetry, biodistribution, stability, safety and PET imaging, encouraging further development of this molecule in various disorders.
Our study, which included a relatively large number of patients confirmed that the 18 F-FDG PET/CT would represent a useful noninvasive diagnostic tool for acute GI-GVHD Indeed, after exclusion of differential diagnosis, acute skin or liver GVHD diagnosis is relatively easy, whereas, diagnosis of GI-GVHD is more complicated. Indeed, despite their lack of sensitivity and specificity, clinical symptoms and endoscopic examination with histology remain the gold standard for GI-GVHD diagnosis. Therefore, we used them here for the reference diagnosis of GI-GVHD in the absence of more sensitive and specific validated alternative. For the same reason, we focused on the maximal GI-GVHD grading, which remain the gold standard. Clinical symptoms have a poor Sp (50% in the study of Neumann et al. 19 ), and cannot distinguish between acute GI-GVHD and other causes of gastrointestinal disorders (particularly infections). On the other hand, there is also no consensus on the role of endoscopy combined with biopsies, as endoscopic procedures are invasive and do not allow for studying the entire gastrointestinal tract. Lethality of endoscopic procedures in allo-SCT patients was reported to be as high as 1.8%. 20 In addition, it is well established that there may be some significant discrepancies between macroscopic morphology of the digestive tract during endoscopy and the presence of histological signs of acute GI-GVHD. 21 In our series, such discrepancies were observed in two patients: histology examination found grade 1 lesions, whereas patients remained always free of acute GI-GVHD. The latter may reflect the absence of consensus for the definition of histological signs of acute GI-GVHD, with the minimum criterion being the presence of apoptotic lesions, although not specific of GI-GVHD. 16, 22 Also, several studies have reported discrepancies between the clinical and histological localizations of acute GI-GVHD, 23, 24 which is represented in our study by the case of one patient who had clinical symptoms of grade 2 acute GI-GVHD, but had a morphologically normal sigmoidoscopy and only grade 1 histological acute GI-GVHD. Therefore, the segment of the gastrointestinal tract that should be biopsied for diagnosis of acute GI-GVHD remains subject to controversy. 25, 26 Finally in our study, we did not expect a correlation between pathology scores and 18 F-FDG PET/CT, as 18 F-FDG PET/CT detects inflammation earlier before the onset of histological lesions, while the pathology score of GI-GVHD is based only on apoptosis and crypt loss 9 and does not take into account endothelial inflammation involved in GI-GVHD but detected by 18 F-FDG PET/CT, for example. One strength of this study is also the high NPV (96%), all patients, but one, with a negative 18 F-FDG PET/CT did not present or develop GI GVHD in the first 100 days after allo-SCT. It could be a valuable tool in patients with full donor chimerism but requiring DLI to assess the risk of GI GVHD onset. Obviously, it is still yet to be established whether a negative 18 F-FDG PET/CT around 1 month after allo-SCT could predict for a GVHD-free course indefinitely or just for a few weeks.
With this background, and given the results of our study, noninvasive 18 F-FDG PET/CT could become a valuable examination to be performed shortly before endoscopy to map acute GI-GVHD lesions, guide the biopsy sites and choose the most appropriate endoscopic procedure (upper or lower endoscopy), especially in those asymptomatic patients with a positive 18 F-FDG PET/CT.
Other procedures are being currently developed in order to refine GI GVHD diagnosis, among others contrast-enhanced ultrasound of the abdomen. 27 However even if this procedure seems less invasive compared with 18 F-FDG PET/CT, it requires i.v. injection of a contrast medium. Furthermore, it requires a specific device and a highly trained physician able to perform the procedure, which are not available in many hospitals, whereas 18 F-FDG PET/CT is available in almost all centres. To avoid the use of invasive endoscopic procedures for GVHD prediction, other approaches has been developed. Paczesny et al. 28 validated four biomarkers (IL-2Ra, TNFR-1, IL-8 and HGF) in the serum of 424 allo-SCT patients. These four biomarkers allowed discrimination of patients with acute GVHD from those patients without acute GVHD with a Sp of 85%. The increase of these biomarkers proved to be an independent prognostic marker of the severity of acute GVHD. More recently, the same group established the value of REG3a, a plasma biomarker of GI-GVHD that can be combined with clinical stage and histologic grade to improve risk stratification of patients. Thus, one would speculate that combining such biomarkers and 18 F-FDG PET/CT results would allow for an optimal noninvasive diagnostic tool to predict acute GI-GVHD. Such studies are warranted because early diagnosis or prediction of acute GI-GVHD would allow for early therapeutic intervention. Conversely, a noninvasive method for predicting the absence or low risk of development of acute GI-GVHD may be also potentially interesting, especially in patients with high-risk malignancies to reduce immunosuppressive therapy more rapidly. In our study, the negative predictive value of PET/CT was 96%, which is a very high level of prediction highlighting the potential value of 18 F-FDG PET/CT. Finally, our study did not find a significant correlation between SUVmax values of bowel loops and the severity of histology lesions. Interestingly, Stelljes et al. 6 have shown in murine preclinical studies a correlation between the severity of GI-GVHD, the value of SUVmax of pathological bowel loops and the level of infiltration of the gastrointestinal mucosa by donor lymphocytes. Furthermore, these authors found in a subgroup of four patients a decrease of SUVmax after therapy raising the possibility for therapeutic monitoring using 18 F-FDG PET/CT. This was not evaluated as part of our analysis, but it is possible that 18 F-FDG PET/CT might also prove useful in monitoring the efficacy of immunosuppressive therapy during acute GI-GVHD treatment.
In all, we conclude that preliminary findings from the current study suggest that 18 F-FDG PET/CT might prove to be a potentially valuable tool for noninvasive diagnosis and prediction of acute GI-GVHD that needs to be validated on a large-scale multicenter level in combination with other recently described biomarkers. Indeed, inflammation associated with GI-GVHD can be detected by 18 F-FDG PET/CT. Further studies should clearly establish whether FDG uptake is always specific for GI-GVHD. However, combination of the new modern tools may have a significant effect on the probability of a favorable GVHD outcome after allo-SCT.
